

UC Riverside

UC Riverside Previously Published Works

Title

Structural Basis for S100B Interaction with its Target Proteins.

Permalink

<https://escholarship.org/uc/item/0zc8j2xq>

Journal

Journal of molecular and genetic medicine : an international journal of biomedical research, 12(3)

ISSN

1747-0862

Authors

Prez, KD
Fan, L

Publication Date

2018

DOI

10.4172/1747-0862.1000366

Peer reviewed



Published in final edited form as:

J Mol Genet Med. 2018 ; 12(3): . doi:10.4172/1747-0862.1000366.

Structural Basis for S100B Interaction with its Target Proteins

KD Prez and L Fan*

Department of Biochemistry, University of California Riverside, 900 University Ave, Riverside, California, USA

Abstract

The S100B protein is an intra- and extracellular signaling protein that plays a role in a multitude of cellular processes and abnormal S100B is associated with various neurological diseases and cancers. S100B recognizes and binds effector proteins in a calcium-dependent manner. S100B has been shown to interact with the actin capping protein CapZ, protein kinase C, Hdm2 and 4, RAGE receptor, and p⁵³, among others. These protein partners interact with a common area on the S100B protein surface, validating the method of using the consensus sequence for S100B target search. In addition, each S100B target protein distinguishes itself by additional contacts with S100B. This perspective suggests that the combination of sequence homology search and structural analysis promises to identify newer S100B-binding partners beyond the use of the consensus sequence alone as the given example in the XPB subunit of the TFIIH general transcription factor. XPB is a helicase required for both transcription and DNA repair. Inherited xpb mutations are associated with human disease Xeroderma Pigmentosum, Cockayne syndrome, and trichothiodystrophy. S100B protein is likely associated with much more biological pathways and processes. We believe that S100B will attract more and more attentions in the scientific community and S100B related studies will have important implications in human health and medicine.

Keywords

Neurological diseases; Cancers; S100B-binding partners; p⁵³ Tumor suppressor; Transcription factor TFIIH; XPB helicase; DNA repair

Introduction

The S100B protein belongs to the S100 family of Ca²⁺-binding signaling proteins which share dual conserved calcium-binding EF-hand motifs. S100 proteins exist exclusively in vertebrates, with 24 members observed in humans [1]. S100B is expressed in astrocytes, Schwann cells, melanocytes, chondrocytes, and adipocytes, among others [2].

This is an open-access article distributed under the terms of the creative commons attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited (<http://creativecommons.org/licenses/by/4.0/>).

*Corresponding author: Dr. Li Fan, Department of Biochemistry, University of California Riverside, 900 University Ave, Riverside, California- 92521, USA, Tel: +1 951-827-1012; lifan@ucr.edu.

Acting as both an intracellular regulator and as a secreted signaling molecule, the S100B protein plays a role in a myriad of cellular processes, including cell proliferation, migration, apoptosis, and differentiation [3–7].

Consequently, aberrant expression levels of S100B have been implicated in a variety of neurological diseases, cancer, and inflammatory disorders [8–14]. As S100B has no intrinsic enzymatic activity, its intra and extracellular functions are achieved exclusively by physical interactions to its target molecules in a calcium-dependent manner.

Currently S100B has been reported to interact with a variety of protein targets including the p53 tumor suppressor, CapZ, the RAGE receptor, NDR kinase, neurotensin, cathepsin L inhibitor, Hdm2, Hdm4, protein kinase C α , ROS-GC1, microtubule-associated tau proteins, melittin, amyloid- β , interleukin-11, the serotonin 5-HT7 receptor, the dopamine D2 receptor and RSK1 [15–29]. This short perspective focuses on the structural basis of S100B-protein interactions.

Literature Review

Structural comparison of S100B-peptide complexes

S100B exists primarily as a homodimer of two approximately 11 kDa monomers (Figure 1A), though stable and active tetrameric, hexameric, and octameric forms have been reported [30]. The S100B monomer consists of four α -helices with a β -strand between both helices 1 and 2, and 3 and 4, composing two helix-loop-helix EF-hand motifs connected by a linker region. The C-terminal canonical motif is made up of 12 amino acids involved in Ca²⁺-ion binding, while the N-terminal EF-hand (also termed the “S100-hand”) contains 14 amino acids, therefore being considered by some as a pseudo-EF-hand because of the extra two amino acids [31,32]. Calcium binding in the N-terminal site I induces limited changes to the structure as a whole (RMSD = 1.472 over 33 atoms), while binding at the C-terminal site II induces a conformational change in helix 3 of up to 90°, leading to the exposure of the binding site for target proteins to access (Figure 1B) [33,34].

S100B interacting protein targets are largely identified by a sequence-based approach using the consensus S100B-interacting sequence ([K/R]-[L/I]-x-W-x-x-I-L). Pioneered by Ivanenkov et al. [18], the sequence was initially proposed based on phage display library screening for bacteriophage exhibiting Ca²⁺-dependent interaction with S100B. Employing the consensus sequence in homology searches revealed the actin capping protein (CapZ) as a potential target [18]. Specifically, the peptide TRTKIDWNKILS, referred to as TRTK-12, was chosen due to its significant homology to the consensus sequence. Further investigation revealed Ca²⁺-dependent interaction between S100B and TRTK-12 or CapZ, leading to the TRTK-12 inhibition of the S100B-CapZ interaction [18]. Subsequent expansion of the S100B-interaction consensus sequence by Wilder et al. to [K/R]-[L/I]-[P/S/N/D]-[W/L/I]-[S/D/L]-x-[L/I]-[L/F] allowed for additional protein targets to be identified and analyzed for S100B interaction. S100B has so far been shown to interact with short peptides derived from protein sequences of the p⁵³ tumor suppressor, CapZ, the RAGE receptor, NDR kinase, neurotensin, cathepsin L inhibitor, Hdm2, Hdm4, protein kinase C α , ROS-GC1 [21,22],

microtubule-associated tau proteins, melittin, amyloid- β , interleukin-11, the serotonin 5-HT7 receptor, the dopamine D2 receptor and RSK1 [15,19–29].

The NMR structure solution of the bovine S100B apo-form yielded the first structural view of a S100B protein [35]. Since then, the past 20 years has seen a wealth of information on S100B conformational variability induced by pH [36], temperature [37], and metal ion-dependence [30,33,38–41]. S100B primarily interacts with its target proteins in the Ca^{2+} -bound state [42]. Other targets, such as the giant phosphoprotein AHNAK, are recognized in a Zn^{2+} dependent manner [43]. Several complexes of Ca^{2+} -bound S100B with short peptides derived from its known targets have been evaluated by NMR and X-ray crystallography, including p⁵³, the NDR kinase, the RAGE receptor, RSK1 and CapZ [19,29,43–48].

The S100B interaction with p⁵³ was first proposed by Baudier et al. based on the similarity of the p⁵³ PKC-phosphorylation site to that of the myristoylated alanine-rich C kinase substrate (MARCKS) protein [49]. MARCKS phosphorylation is inhibited by EF-hand proteins, including S100B, though the MARCKS PKC-site is not in a good agreement with the S100B consensus sequence [50]. In addition, another region of p⁵³ capable of interacting with S100B was identified in the p⁵³ oligomerization domain [17]. S100B thus inhibits p⁵³ oligomerization [4], as well as phosphorylation by PKC at the p⁵³ C-terminus [49]. It was further shown that a peptide derived from the p⁵³ carboxy-terminal regulatory domain (CTD) could be phosphorylated by PKC, and this activity could be inhibited by S100B [16]. Such inhibition events consequently reduce the p⁵³ transcriptional activity, preventing its stimulation of cell cycle arrest and apoptosis [4].

To counteract the deleterious effects of S100B on p⁵³ activity, small molecule screening studies have revealed several inhibitors of the S100B-p⁵³ interaction including pentamidine (Pnt) in the form of pentamidine isethionate, an antiprotozoal drug currently approved for treatment of *Pneumocystis carinii* pneumonia [51,52]. Pnt has been shown to disrupt the S100B-p⁵³ complex, resulting in increased cell apoptosis, p⁵³ expression, and decreased cell migration [53]. Phase II clinical trial results revealed a myriad of adverse effects during melanoma treatment with Pnt (www.clinicaltrials.gov, identifier NCT00729807). Structure solution of the S100B-Pnt complex showed two Pnt molecules bound per monomer, occupying two sites adjacent to the p⁵³ binding surface [40]. Further screening studies found several potential inhibitors binding in the hydrophobic cleft of the p⁵³ binding site [52,54]. These findings together show three binding sites for drug inhibitors of the S100B-p⁵³ interaction. Currently, the goal is to design inhibitors that span all three sites, likely providing higher affinity and specificity for S100B binding. The Weber group has performed several studies investigating small molecules binding in the three different sites and identifying the so called “FF-gate” composed of Phe87 and Phe88, normally occupying a channel between sites 1 and 2, occluded by a Pnt analog [52,55–57]. They also identified molecules exclusive to site 3 [56]. With the extensive structural and biochemical data available, a potent inhibitor of the S100B-p⁵³ complex formation seems right around the corner.

Discussion

Structural analysis of the complex between S100B and a p⁵³-CTD peptide (amino acids 367–388) revealed an induced folding of the peptide, normally unstructured, into an α -helical structure (Figure 2A) [44]. This same induced helical fold is observed in other targets of S100B: RSK1, RAGE, and the NDR kinase (Figure 2B). While all three of these peptides adopt a similar fold when bound to S100B and share a common binding area on the surface of S100B, each target protein does distinguish itself by additional contacts with S100B. In the complex of S100B with an NDR kinase peptide, several hydrophobic contacts are made between NDR side chains and the hydrophobic core of the S100B binding site [19]. In addition, electrostatic interactions are observed between helical side chains from NDR with the linker region of S100B [19]. In the S100B-RSK1 study, Gogl et al. used several peptides to generate co-crystals of the protein-peptide complex, resulting in several crystal structures showing altered binding of peptide(s) to S100B dimers [29]. These interactions have been confirmed by SAXS analysis and NMR NOE assignments [29]. Two of the four tested peptides adopted a helical fold extending through the binding pocket of S100B, with one nearly extending into the unbound S100B subunit of the dimer (Figure 2B). Both structures, however, seem to bypass completely the canonical hydrophobic binding pocket of Ca²⁺-bound S100B, with primarily hydrogen bonding and electrostatic interactions with the S100B linker and surface residues facilitating the interaction. Binding of the RAGE peptide, on the other hand, relies almost exclusively on the S100B hydrophobic binding pocket [45]. With minimal hydrogen bonding and no clear salt bridge formation between the peptide and S100B, the interaction is maintained via burying three hydrophobic residues in the S100B site after the induced helical fold of the peptide (Figure 2B). Indeed, the diversity observed in the interaction surfaces among S100B and its target proteins reveals an extremely large binding surface on S100B allowing for binding a diverse selection of peptide sequences (Figure 2B) [15].

To quantitatively compare the interaction energies of the S100B-peptide complexes, we analyzed the structure models using the Proteins, Interfaces, Structures and Assemblies (PISA) server [58]; the results are summarized in Table 1. The results of the PISA analysis compared to the dissociation constants reported for the different complexes reveal a strong correlation between the ΔG of solvation and the K_d values. One exception was the TRTK-12 peptide, though this is likely due to the exceptionally hydrophobic nature of its interface as evidenced by its low ΔG P-value. Indeed, the strongest interaction ($K_d = 0.04 \pm 0.02 \mu\text{M}$) coincides with the largest ΔG (–13.4 kcal/mol) in the RSK1-A peptide while the weakest interaction ($K_d = 23.5 \pm 6.6$) has the smallest ΔG (–5.0 kcal/mol) in the p⁵³ peptide-S100B complex.

This apparent correlation between the *in silico* and *in vitro* quantitative data suggests that known structures can be used as the guidance to identify new S100B targets of high-affinity. As the pool of available S100B-target peptide complex structures grows, it has become clear that the S100B-interaction consensus sequence is largely limiting in that the specific residues involved in interaction with S100B vary greatly between peptide sequences [15]. To reflect this in the search for new S100B targets, specific peptide sequences should be used together with structural homology of the interacting residues. Utilizing this new approach,

we identified a new potential target of S100B in the XPB helicase subunit of the general transcription factor TFIIH.

XPB-S100B proposed interaction

The Xeroderma pigmentosum complementation group B (XPB) helicase is the largest subunit of the general transcription factor II (TFIIH) complex. XPB plays vital roles in both transcription and nucleotide excision repair [59]. Being an ATP-dependent 3'-5' helicase, the XPB helicase facilitates the opening of the DNA helix during NER to allow for removal of bulky DNA adducts generated as a consequence of UV exposure or chemical therapies for anticancer treatment [59,60]. In addition, the XPB ATPase activity is critical for initiation and promoter melting during transcription [61–63].

Several structural studies have provided a framework for how XPB functions as a molecular wrench to melt dsDNA both alone [64,65] and in the context of TFIIH [66–68]. In addition, a high-resolution crystal structure by Hilario et al. provided a model for how the proposed XPB-XPF complex forms to facilitate the 5' -incision during NER [69]. Phosphorylation of Ser751 in the C-terminus of XPB acts as a key regulatory site during NER via modulating XPF activity [70]. Furthermore, we notice that the XPB extreme C-terminus shares sequence homology with key residues of the p⁵³-CTD, and so we propose that XPB should interact with S100B in a similar fashion to that of the p⁵³-S100B complex [44]. Interestingly, such interaction was postulated previously by Lin et al. based on the XPB-p⁵³ C-terminal interaction [4]. XPB could block the inhibitory S100B targeting of p⁵³ in a competitive manner. A similar mode of regulation was proposed for the S100B-RSK1 complex by Gogl et al. Based on their structural modeling, S100B binding could block ERK2 binding to RSK1, and thus inhibit the phosphorylation of the RSK1 activation loop [29]. This inhibition of RSK1 phosphorylation by S100B, coupled with its inhibition of the RSK1 C-terminal kinase domain, explains how S100B blocks the MAPK signal cascade via RSK1 in malignant melanoma [29]. In a similar fashion, S100B-XPB interactions could have a regulatory role in transcription and/or DNA repair. Specifically, S100B binding to the XPB C-terminal tail could interfere with the phosphorylation of Ser751 of XPB and/or dephosphorylation, resulting in inhibition or stimulation, respectively, of the XPF endonuclease during DNA repair [70]. Alternatively, S100B could physically block the interaction of XPB with the XPF endonuclease complex directly.

Although the amino acid sequences of the XPB and p⁵³ extreme C-termini share low sequence homology (~23% using BLAST), most of the conserved residues in p⁵³ form direct contacts with S100B in the S100B-p⁵³ peptide complex (PDB entry 1DT7) (Figures 3A and 3B). Specifically, Arg379, His380, Lys382, Met384, Phe385, and Lys386 of the p⁵³ peptide show direct contacts with residues of S100B, implying similar interactions in the S100B-XPB complex involving the identical or similar residues Lys771, His772, His774, Leu776, Phe777, and Lys778 of XPB, respectively. Our preliminary results do suggest a stable complex formed between S100B and the XPB C-terminal half consisting of residues 494–782 (Figure 4). During gel filtration chromatography, the peaks of individual XPB and S100B are both shifted to a higher apparent molecular weight when the two proteins are mixed together (Figure 4A). Furthermore, we noticed that a degraded XPB protein (XPBc-

) lack of the last 52 residues did not shift, in agreement with our prediction that XPB interacts with S100B via its C-terminal residues. These observations confirm that the sequence conservation between the C-termini of XPB and p⁵³ seems sufficient for the interactions with S100B. However, one important discrepancy lies with Leu383 of p⁵³, as the corresponding residue of XPB is Pro775. The presence of a proline residue in the XPB sequence would prevent formation of an alpha-helical structure in this region of XPB due to the geometric restrictions of the proline side-chain. This would suggest some changes in the S100B-XPB interface compared to that of S100B-p53 complex. It will be very interesting to further investigate the structural features of the S100B-XPB interface and the biological impact of such an interaction (Figure 4B).

Conclusion and Future Research

In this review, we analyzed the structural basis of the S100B-peptide interactions on available data and literature information. Besides the common binding area shared by all S100B interacting proteins, the additional contacts provided by each target warrant the limitation of sequence only search in identifying new S100B target proteins. We believe that the combinatorial sequence/structure-homology approach for S100B target identification will expand new S100B targets beyond the use of sequence-based searches alone. The identification of the XPB protein as a new S100B target likely reveals a new means of regulating transcription and/or DNA repair through S100B. With the diversity of targets already identified, the processes involving S100B, and other S100 proteins, are likely far more extensive than what we currently know and could have important implications in human health and medicine.

Acknowledgement

This work is partially supported by US NIH grant R01GM108893 awarded to L.F.

References

1. Donato R (2001) S100: A multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. *Int J Biochem Cell Biol* 33: 637–668. [PubMed: 11390274]
2. Donato R, Sorci G, Riuzzi F, Arcuri C, Bianchi R, et al. (2009) S100B's double life: Intracellular regulator and extracellular signal. *Biochim Biophys Acta* 1793: 1008–1022. [PubMed: 19110011]
3. Hachem S, Laurenson A, Hugnot JP, Legraverend C (2007) Expression of S100B during embryonic development of the mouse cerebellum. *BMC Dev Biol* 7: 17. [PubMed: 17362503]
4. Lin J, Blake M, Tang C, Zimmer D, Rustandi RR, et al. (2001) Inhibition of p⁵³ transcriptional activity by the S100B calcium-binding protein. *J Biol Chem* 276: 35037–35041. [PubMed: 11454863]
5. Lin J, Yang Q, Wilder PT, Carrier F, Weber DJ (2010) The calcium-binding protein S100B down-regulates p⁵³ and apoptosis in malignant melanoma. *J Biol Chem* 285: 27487–27498. [PubMed: 20587415]
6. Tubaro C, Arcuri C, Giambanco I, Donato R (2010) S100B protein in myoblasts modulates myogenic differentiation via NF-kappaB-dependent inhibition of MyoD expression. *J Cell Physiol* 223: 270–282. [PubMed: 20069545]
7. Tubaro C, Arcuri C, Giambanco I, Donato R (2011) S100B in myoblasts regulates the transition from activation to quiescence and from quiescence to activation and reduces apoptosis. *Biochem Biophys Acta* 1813: 1092–1104. [PubMed: 21130124]

8. Liu J, Wang H, Zhang L, Xu Y, Deng W, et al. (2011) S100B transgenic mice develop features of Parkinson's disease. *Arch Med Res* 42: 1–7. [PubMed: 21376255]
9. Schroeter ML, Abdul-Khaliq H, Sacher J, Steiner J, Blasig IE, et al. (2010) Mood disorders are glial disorders: Evidence from in vivo studies. *Cardiovasc Psychiatry Neurol* 1: 780.
10. Rothermundt M, Ahn JN, Jorgens S (2009) S100B in schizophrenia: An update. *Gen Physiol Biophys* 28 1: F76–81.
11. Mocellin S, Zavagno G, Nitti D (2008) The prognostic value of serum S100B in patients with cutaneous melanoma: A meta-analysis. *Int J Cancer* 123: 2370–2376. [PubMed: 18752249]
12. Jiang W, Jia Q, Liu L, Zhao X, Tan A, et al. (2011) S100B promotes the proliferation, migration and invasion of specific brain metastatic lung adenocarcinoma cell line. *Cell Biochem Funct* 29: 582–588. [PubMed: 21861268]
13. Jung K, Goerdts C, Lange P, Blocher J, Djukic M, et al. (2011) The use of S100B and Tau protein concentrations in the cerebrospinal fluid for the differential diagnosis of bacterial meningitis: a retrospective analysis. *Eur Neurol* 66: 128–132. [PubMed: 21865761]
14. Hearst SM, Walker LR, Shao Q, Lopez M, Raucher D, et al. (2011) The design and delivery of a thermally responsive peptide to inhibit S100B-mediated neurodegeneration. *Neurosci* 197: 369–380.
15. Wilder PT, Lin J, Bair CL, Charpentier TH, Yang D, et al. (2006) Recognition of the tumor suppressor protein p53 and other protein targets by the calcium-binding protein S100B. *Biochim Biophys Acta* 1763: 1284–1297. [PubMed: 17010455]
16. Rustandi RR, Drohat AC, Baldissieri DM, Wilder PT, Weber DJ (1998) The Ca²⁺-dependent interaction of S100B (beta beta) with a peptide derived from p53. *Biochem* 37: 1951–1960. [PubMed: 9485322]
17. Fernandez-Fernandez MR, Veprintsev DB, Fersht AR (2005) Proteins of the S100 family regulate the oligomerization of p53 tumor suppressor. *Proc Natl Acad Sci USA* 102: 4735–4740. [PubMed: 15781852]
18. Ivanenkov VV, Jamieson GA, Gruenstein E, Dimlich RVW (1995) Characterization of S-100b binding epitopes. Identification of a novel target, the actin capping protein. *CapZ J Biol Chem* 270: 14651–14658. [PubMed: 7540176]
19. Bhattacharya S, Large E, Heizmann CW, Hemmings BA, Chazin WJ (2003) Structure of the Ca²⁺/S100B/NDR kinase peptide complex: insights into S100 target specificity and activation of the kinase. *Biochemis* 42: 14416–14426.
20. Wilder PT, Rustandi RR, Drohat AC, Weber DJ (1998) S100B (Beta-Beta) inhibits the protein kinase C-dependent phosphorylation of a peptide derived from p53 in a Ca²⁺-dependent manner. *Protein Sci* 7: 794–798. [PubMed: 9541413]
21. Duda T (2002) Ca (2+) sensor S100beta-modulated sites of membrane guanylate cyclase in the photoreceptor-bipolar synapse. *EMBO J* 21: 2547–2556. [PubMed: 12032068]
22. Duda T, Sharma RK (2004) S100B-modulated Ca²⁺-dependent ROS-GC1 transduction machinery in the gustatory epithelium: A new mechanism in gustatory transduction. *FEBS Lett* 577: 393–398. [PubMed: 15556616]
23. Baudier J, Mochly-Rosen D, Newton A, Lee SH, Koshland DE, et al. (1987) Comparison of S100b protein with calmodulin: interactions with melittin and microtubule-associated tau proteins and inhibition of phosphorylation of tau proteins by protein kinase C. *Biochem* 26: 2886–2893. [PubMed: 3111527]
24. Cristovao JS (2018) The neuronal S100B protein is a calcium-tuned suppressor of amyloid-beta aggregation. *Sci Adv* 4: 1702.
25. Kazakov AS, Sokolov AS, Vologzhannikova AA, Permyakova ME, Khorn PA, et al. (2017) Interleukin-11 binds specific EF-hand proteins via their conserved structural motifs. *J Biomol Struct Dyn* 35: 78–91. [PubMed: 26726132]
26. Stroth N, Svenningsson P (2015) S100B interacts with the serotonin 5-HT₇ receptor to regulate a depressive-like behavior. *Eur Neuropsychopharmacol* 25: 2372–2380. [PubMed: 26499172]
27. Dempsey BR, Shaw GS (2011) Identification of calcium-independent and calcium-enhanced binding between S100B and the dopamine D2 receptor. *Biochem* 50: 9056–9065. [PubMed: 21932834]

28. Hartman KG, Vitolo MI, Pierce AD, Fox JM, Shapiro P, et al. (2014) Complex formation between S100B protein and the p90 ribosomal S6 kinase (RSK) in malignant melanoma is calcium-dependent and inhibits extracellular signal-regulated kinase (ERK)-mediated phosphorylation of RSK. *J Biol Chem* 289: 12886–12895. [PubMed: 24627490]
29. Gogl G, Alexa A, Kiss B, Katona G, Kovács M, et al. (2016) Structural basis of ribosomal s6 kinase 1 (RSK1) inhibition by S100B protein: Modulation of the extracellular signal-regulated kinase (ERK) signaling cascade in a calcium-dependent way. *J Biol Chem* 291: 11–27. [PubMed: 26527685]
30. Ostendorp T, Leclerc E, Galichet A, Koch M, Demling N, et al. (2007) Structural and functional insights into RAGE activation by multimeric S100B. *EMBO J* 26: 3868–3878. [PubMed: 17660747]
31. Kligman D, Hilt DC (2013) The S100 protein family. *Trends Biochem Sci* 13: 437–43.
32. Donato R (2010) Functions of S100 proteins. *Curr Mol Med* 13: 24–57.
33. Smith S, Shaw GS (1998) A change-in-hand mechanism for S100 signalling. *Biochem Cell Biol* 76: 324–333. [PubMed: 9923701]
34. Zimmer DB, Sadosky W, Weber DJ (2003) Molecular mechanisms of S100-target protein interactions. *Microsc Res Tech* 60: 552–559. [PubMed: 12645003]
35. Kilby PM, Eldik LJ, Roberts GC (1996) The solution structure of the bovine S100B protein dimer in the calcium-free state. *Structure* 4: 1041–1052. [PubMed: 8805590]
36. Ostendorp T (2011) The crystal structures of human S100B in the zinc- and calcium-loaded state at three pH values reveal zinc ligand swapping. *Biochim Biophys Acta* 1813: 1083–1091. [PubMed: 20950652]
37. Malik S (2008) Analysis of the structure of human apo-S100B at low temperature indicates a unimodal conformational distribution is adopted by calcium-free S100 proteins. *Proteins* 73: 28–42. [PubMed: 18384084]
38. Drohat AC, Baldisseri DM, Rustandi RR, Weber DJ (1998) Solution structure of calcium-bound rat S100B(betabeta) as determined by nuclear magnetic resonance spectroscopy. *Biochem* 37: 2729–2740. [PubMed: 9485423]
39. Wilder PT, Varney KM, Weiss MB, Gitti RK, Weber DJ (2005) Solution structure of zinc- and calcium-bound rat S100B as determined by nuclear magnetic resonance spectroscopy. *Biochemi* 44: 5690–5702.
40. Charpentier TH, Wilder PT, Liriano MA, Varney KM, Pozharski E, et al. (2008) Divalent metal ion complexes of S100B in the absence and presence of pentamidine. *J Mol Biol* 382: 56–73. [PubMed: 18602402]
41. Charpentier TH, Wilder PT, Liriano MA, Varney KM, Zhong S, et al. (2009) Small molecules bound to unique sites in the target protein binding cleft of calcium-bound S100B as characterized by nuclear magnetic resonance and X-ray crystallography. *Biochem* 48: 6202–6212 [PubMed: 19469484]
42. Rezvanpour A, Shaw GS (2009) Unique S100 target protein interactions. *Gen Physiol Biophys* 1: F39–46.
43. Gentil BJ, Delphin C, Mbele GO, Deloulme JC, Ferro M, et al. (2001) The giant protein AHNK is a specific target for the calcium- and zinc-binding S100B protein: potential implications for Ca^{2+} homeostasis regulation by S100B. *J Biol Chem* 276: 23253–23261. [PubMed: 11312263]
44. Rustandi RR, Baldisseri DM, Weber DJ (2000) Structure of the negative regulatory domain of p53 bound to S100B (betabeta). *Nat Struct Biol* 7: 570–574. [PubMed: 10876243]
45. Jensen JL, Indurthi VSK, Neau DB, Vetter SW, Colbert CL (2015) Structural insights into the binding of the human receptor for advanced glycation end products (RAGE) by S100B, as revealed by an S100B- RAGE-derived peptide complex. *Acta Crystallogr D Biol Crystallogr* 71: 1176–1183. [PubMed: 25945582]
46. Inman KG, Yang R, Rustandi RR, Miller KE, Baldisseri DM, et al. (2002) Solution NMR structure of S100B bound to the high-affinity target peptide TRTK-12. *J Mol Biol* 324: 1003–1014. [PubMed: 12470955]

47. Charpentier TH, Thompson LE, Liriano MA, Varney KM, Wilder PT, et al. (2010) The effects of CapZ peptide (TRTK-12) binding to S100B-Ca²⁺ as examined by NMR and X-ray crystallography. *J Mol Biol* 396: 1227–1243. [PubMed: 20053360]
48. McClintock KA, Shaw GS (2003) A novel S100 target conformation is revealed by the solution structure of the Ca²⁺-S100B-TRTK-12 complex. *J Biol Chem* 278: 6251–6257. [PubMed: 12480931]
49. Baudier J, Delphin C, Grunwald D, Khochbin S, Lawrence JJ, et al. (1992) Characterization of the tumor suppressor protein p53 as a protein kinase C substrate and a S100b-binding protein. *Proc Natl Acad Sci USA* 89: 11627–11631. [PubMed: 1454855]
50. Albert KA (1984) Inhibition by calmodulin of calcium/phospholipid- dependent protein phosphorylation. *Proc Natl Acad Sci USA* 81: 3622–3625. [PubMed: 6233611]
51. Markowitz J, Chen I, Gitti R, Baldisseri DM, Pan Y, et al. (2004) Identification and characterization of small molecule inhibitors of the calcium-dependent S100B-p53 tumor suppressor interaction. *J Med Chem* 47: 5085–5093. [PubMed: 15456252]
52. Weber D (2010) In vitro screening and structural characterization of inhibitors of the S100B-p53 interaction. *Int J High Throughput Screen* 2010: 109–126. [PubMed: 21132089]
53. Capoccia E, Cirillo C, Marchetto A, Tiberi S, Sawikr Y, et al. (2015) S100B-p53 disengagement by pentamidine promotes apoptosis and inhibits cellular migration via aquaporin-4 and metalloproteinase-2 inhibition in C6 glioma cells. *Oncol Lett* 9: 2864–2870. [PubMed: 26137161]
54. Agamennone M, Cesari L, Lalli D, Turlizzi E, Conte RD, et al. (2010) Fragmenting the S100B-p53 interaction: combined virtual/biophysical screening approaches to identify ligands. *Chem Med Chem* 5: 428–435. [PubMed: 20077460]
55. Cavalier MC (2016) Small molecule inhibitors of Ca²⁺-S100B reveal two protein conformations. *J Med Chem* 59: 592–608. [PubMed: 26727270]
56. Cavalier MC, Melville Z, Aligholizadeh E, Raman EP, Yu W, et al. (2016) Novel protein-inhibitor interactions in site 3 of Ca²⁺ bound S100B as discovered by X-ray crystallography. *Acta Crystallogr D Struct Biol* 72: 753–760. [PubMed: 27303795]
57. Cavalier MC, Pierce AD, Wilder PT, Alasady MJ, Hartman KG, et al. (2014) Covalent small molecule inhibitors of Ca²⁺ bound S100B. *Biochem* 53: 6628–6640. [PubMed: 25268459]
58. Krissinel E, Henrick K (2007) Inference of macromolecular assemblies from crystalline state. *J Mol Biol* 372: 774–797. [PubMed: 17681537]
59. Schaeffer L, Roy R, Humbert S, Moncollin V, Vermeulen W, et al. (1993) LDNA repair helicase: A component of BTF2 (TFIIH) basic transcription factor. *Sci* 260: 58–63.
60. Fuss JO, Tainer JA (2011) XPB and XPD helicases in TFIIH orchestrate DNA duplex opening and damage verification to coordinate repair with transcription and cell cycle via CAK kinase. *DNA Repair* 10: 697–713. [PubMed: 21571596]
61. Bradsher J, Coin F, Egly JM (2000) Distinct roles for the helicases of TFIIH in transcript initiation and promoter escape. *J Biol Chem* 275: 2532–2538. [PubMed: 10644710]
62. Kim TK (2000) Mechanism of ATP-dependent promoter melting by transcription factor IIH. *Sci* 288: 1418–1422.
63. Coin F, Oksenyich V, Egly JM (2007) Distinct roles for the XPB/p52 and XPD/p44 subcomplexes of TFIIH in damaged DNA opening during nucleotide excision repair. *Mol Cell* 26: 245–256. [PubMed: 17466626]
64. Fan L, Arvai AS, Cooper PK, Iwai S, Hanaoka F, et al. (2006) Conserved XPB core structure and motifs for DNA unwinding: implications for pathway selection of transcription or excision repair. *Mol Cell* 22: 27–37. [PubMed: 16600867]
65. Kahanda D, DuPrez KT, Hilario E, McWilliams MA, Wohlgamuth CH, et al. (2018) Application of electrochemical devices to characterize the dynamic actions of helicases on DNA. *Anal Chem* 90: 2178–2185. [PubMed: 29285929]
66. Plaschka C, Hantsche M, Dienemann C, Burzinski C, Plitzko J, et al. (2006) Transcription initiation complex structures elucidate DNA opening. *Nature* 533: 353–358.
67. Schilbach S, Hantsche M, Tegunov D, Dienemann C, Wigge C, et al. (2007) Structures of transcription pre-initiation complex with TFIIH and mediator. *Nature* 551: 204–209.

68. Luo J, Cimerancic P, Viswanath S, Ebmeier CC, Kim B, et al. (2015) Architecture of the human and yeast general transcription and DNA repair factor TFIIH. *Mol Cell* 59: 794–806. [PubMed: 26340423]
69. Hilario E, Li Y, Nobumori Y, Liu X, Fan L (2013) Structure of the C- terminal half of human XPB helicase and the impact of the disease- causing mutation XP11BE. *Acta Crystallogr D Biol Crystallogr* 69: 237–246. [PubMed: 23385459]
70. Coin F, Auriol J, Tapias A, Clivio P, Vermeulen W, et al. (2004) Phosphorylation of XPB helicase regulates TFIIH nucleotide excision repair activity. *EMBO J* 23: 4835–4846. [PubMed: 15549133]




Figure 1:

S100B dimer and Calcium induced conformational changes. (A) S100B Ca²⁺-bound dimer in ribbon representation (PDB entry 2h61). Monomers are colored in grey and cyan. The C-terminal EF-hand motif of the cyan monomer is colored red, while the N-terminal pseudo-EF-hand motif is colored blue. EF-hand bound Ca²⁺ ions are shown as yellow spheres. (B) Alignment of apo-S100B (magenta; PDB entry 1b4c) and Ca²⁺-bound (green; PDB entry 2h61) S100B, shown as in A. Ca²⁺-induced Helix 3 rearrangement is highlighted with a red oval.




Figure 2: Structural comparison of the S100B-peptide interfaces. (A) The S100B-p⁵³ peptide complex (PDB entry 1dt7). (Left) S100B is shown as a gray surface with the p⁵³ peptide in cartoon representation (red). (Right) Residue properties of the p⁵³-binding pocket (white – hydrophobic, green – polar, blue – basic, red – acidic). (B) Common S100B-peptide interaction surface. (Left) S100B from the NDR-kinase model (PDB entry 1psb) shown as a gray surface with the peptides of NDR (magenta), RAGE (green; PDB entry 4xyn), RSK1 (pink; PDB entry 5csn, blue; PDB entry 5csj, yellow; PDB entry 5csi, cyan; PDB entry 5csf), and TRTK-12 (orange; PDB entry 1mq1) based on superposition of the S100B C-terminus (aa 29–88). (Middle) S100B dimer surface colored according to the bound peptides on the left with common-binding area in black. (Right) Residue properties of the peptide-binding pocket (white – hydrophobic, green – polar, blue – basic, red – acidic).




Figure 3:
 The XPB-S100B interaction likely resembles the p53- S100B complex. (A) A BLAST sequence alignment of the XPB C- terminus with the p53 negative regulatory domain. Unconservative interacting residues are highlighted in magenta. (B) Stereo-view of the S100B (cyan) complex with p53 (green) interacting region (PDB entry 1DT7) shown in cartoon representation, with residues composing the interface displayed in sticks. Unconservative interacting residues of p53 with XPB are shown with carbons in magenta. The bound calcium ion is shown as a pink sphere.




Figure 4:

Interaction of XPB with S100B. (A) Gel filtration chromatography profile of the XPB C-terminal half (amino acids 494–782) alone (dashes), S100B dimer alone (dots), or the mixture of the two (solid). The peak shift of the mixed sample compared to those of XPBc and S100B indicates the formation of a stable S100B-XPBc complex. The calibration protein elution positions, demarcated by vertical lines for clarity, were generated from a mix of aldolase (158 kDa, Ald), ovalbumin (44 kDa, Ova), and lactalbumin (14 kDa, Lac) protein standards. (B) SDS-PAGE analysis of the chromatography profiles in (A). Protein bands – XPBc (494–782); XPBc- (494–730, XPBc degraded during purification [69]); M – marker, # – elution volume fraction.

Table 1:

PISA analysis of S100B-peptide complex structures.

PDB Entry	Peptide	Interface Area (Å ²)	G (kcal/mol)	G P-value	K _d (M)	Reference
1di7	p53 (367–388)	480.0 ^b	-7.3 ^b	0.328 ^b	23.5 +/- 6.6	[44]
1psb	NDR (62–87)	689.2 ^b	-9.3 ^b	0.328 ^b	20 +/- 10	[19]
4xyn	RAGE (54–68)	466.9	-8.7	0.253	2.7 +/- 0.5	[45]
1mq1	TRTK-12 (265–276)	525.7 ^b	-9.9 ^b	0.131 ^b	0.27 +/- 0.03	[48]
5csf	RSK1-A (683–735)	590.4 ^c	-13.4 ^c	0.465 ^d	0.04 +/- 0.02	[29]
5csi	RSK1-A' (689–735)	716.0 ^c	-12.1 ^c	0.491 ^d	1.8 +/- 0.3	[29]
5csj	RSK1-B (696–735)	583.9 ^c	-12.2 ^c	0.464 ^d	2.5 +/- 0.2	[29]
5csn	RSK1-C (683–720)	714.0 ^c	-9.2 ^c	0.632 ^d	9.6 +/- 1.4	[29]

^aThe amino acids are color coded as follows based on the PISA analysis: Red – interfacing residue with S100B; black – non-interfacing residue; grey – not modeled in the PDB Entry.

^bMean value for both asymmetric S100B monomers of all NMR conformers submitted.

^cSum of values for the peptide interactions with both asymmetric S100B monomers.

^dMean value for the peptide interactions with both asymmetric S100B monomers